Metformin alleviates bone loss in ovariectomized mice through inhibition of autophagy of osteoclast precursors mediated by E2F1

Xudong Xie1,2†, Liangcong Hu1,2†, Bobin Mi1,2†, Hang Xue1,2, Yiqiang Hu1,2, Adriana C. Panayi3, Yori Endo3, Lang Chen1,2, Chenchen Yan1,2, Ze Lin1, Hui Li1,2*, Wu Zhou1,2* and Guohui Liu1,2*

Abstract

Background: Postmenopausal bone loss, mainly caused by excessive bone resorption mediated by osteoclasts, has become a global public health burden. Metformin, a hypoglycemic drug, has been reported to have beneficial effects on maintaining bone health. However, the role and underlying mechanism of metformin in ovariectomized (OVX)-induced bone loss is still vague.

Results: In this study, we demonstrated for the first time that metformin administration alleviated bone loss in postmenopausal women and ovariectomized mice, based on reduced bone resorption markers, increased bone mineral density (BMD) and improvement of bone microstructure. Then, osteoclast precursors administered metformin in vitro and in vivo were collected to examine the differentiation potential and autophagical level. The mechanism was investigated by infection with lentivirus-mediated BNIP3 or E2F1 overexpression. We observed a dramatical inhibition of autophagosome synthesis and osteoclast formation and activity. Treatment with RAPA, an autophagy activator, abrogated the metformin-mediated autophagy downregulation and inhibition of osteoclastogenesis. Additionally, overexpression of E2F1 demonstrated that reduction of OVX-upregulated autophagy mediated by metformin was E2F1 dependent. Mechanistically, metformin-mediated downregulation of E2F1 in ovariectomized mice could downregulate BECN1 and BNIP3 levels, which subsequently perturbed the binding of BECN1 to BCL2. Furthermore, the disconnect between BECN1 and BCL2 was shown by BNIP3 overexpression.

Conclusion: In summary, we demonstrated the effect and underlying mechanism of metformin on OVX-induced bone loss, which could be, at least in part, ascribed to its role in downregulating autophagy during osteoclastogenesis via E2F1-dependent BECN1 and BCL2 downregulation, suggesting that metformin or E2F1 inhibitor is a potential agent against postmenopausal bone loss.

Keywords: Metformin, Osteoclast precursors, Bone loss, Autophagy, E2F1, BECN1, BNIP3

© The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
to osteoporosis and other osteolytic conditions, such as postmenopausal osteoporosis [1, 2]. Therefore, inhibition of osteoclast formation and activation is a crucial therapeutic strategy for treating postmenopausal bone loss, such as the use of bisphosphonates, denosumab, and teriparatide. These drugs have been clinically ratified and show a favorable treatment effect in osteoporosis [3], but there are some adverse effects on other organs because of failure specifically target bone [4, 5]. Thus, novel drugs with low toxicity and/or more specific targets are necessary.

Osteoclasts originate from monocytes/macrophages of the hematopoietic lineage in bone marrow, which become multinucleated bone-resorbing osteoclasts via proliferation and differentiation [6]. Among them, macrophage colony-stimulating factor (M-CSF) and the receptor activator of nuclear factor-kB (RANK) ligand (RANKL) are regarded as crucial cytokines for formation of functional osteoclasts [1, 7, 8]. In addition to this canonical RANKL activation signaling pathway, autophagy, the major catabolic process of eukaryotic cells known to breakdown and recycle a wide array of cytoplasmic components [9, 10], actively participates in both the differentiation and bone-resorbing function of osteoclasts [11], in which the elevated level of autophagic activity is beneficial to osteoclasts formation and survival [12, 13]. Additionally, autophagy has also been demonstrated to be indispensable in the function of osteoclasts, in which the bone-resorbing activity is sharply reduced when osteoclast precursors were treated with bafilomycin, a specific inhibitor of vacuolar H\(^{+}\)-ATPases and autophagy inhibitor. Inhibition of autophagy alleviates bone loss induced by glucocorticoid and ovariectomy [14]. Therefore, although different autophagy-inducing or intervening agents have different effects on the normal function and differentiation of osteoclasts, the previous basic and clinical studies have basically confirmed that autophagy affects the osteoclastogenesis. Thus, autophagy inhibition may be an effective strategy for rescuing bone loss through downregulation of autophagy during osteoclastogenesis.

Metformin is the most commonly used hypoglycemic drug for patients with Type 2 diabetes mellitus (T2DM) because of its few side effects. Beyond that, it has also been proved that prior treatment with metformin is linked to reduced risk of osteoporosis in adult women without T2DM and obesity and fractures, particularly hip fractures [15, 16]. It has also been demonstrated that metformin plays a protective role in bone mass preservation under conditions of estrogen deficiency through an increase of osteoprotegerin (OPG) and decrease of RANKL expression [17]. In addition, studies indicated that metformin ameliorated arthritis through inhibition of osteoclastogenesis by suppressing the STAT3 and AMPK pathway and the expression of proinflammatory cytokines [18, 19]. However, current studies showed that metformin, as an autophagy modulator, is widely involved in various tissues protection, including the heart [20], kidney [21], and brain [22], but no such evidence has been proven yet for bone. Therefore, we hypothesized that metformin could inhibit osteoclast formation and activation by regulating autophagy during osteoclastogenesis in ovariectomized mice. Furthermore, deciphering the cellular and molecular mechanisms that metformin suppresses osteoclast activation is of seminal importance for understanding and treating bone loss and the development of osteoporosis.

Current studies have shown that metformin could reduce osteoclast number and inhibit osteoclast activation, and prevent bone loss through suppression of RANKL signaling and AMPK/ NF-κb/ERK signaling pathway [17, 26, 27]. Additionally, in bone mesenchymal cells (BMSCs), strong experimental evidence indicates metformin is beneficial in bone formation and these effects may be partly attributed to activation of osteogenic differentiation by metformin via regulation of AMPK expression [23–25]. Thus, metformin is likely to be used for the prevention and treatment of bone loss when more information involving the effect of metformin in osteoclastogenesis becomes known. However, the premise is that the specific mechanism needs to be prior surfaced and proven.

**Materials and methods**

**Reagents**

Metformin was purchased from Sigma-Aldrich. The primary antibodies of GAPDH, BECN1, LC3, BNI3, BCL2 and E2F1 were acquired from Proteintech (Wuhan, China). The 4, 6-diamidino-2-phenylindole (DAPI) was purchased from Solarbio (Beijing, China). The 4, 6-diamidino-2-phenylindole (DAPI) was obtained from R&D Systems (Minnesota, USA). We purchased Minimum Essential Medium Alpha (MEM-α), fetal bovine serum (FBS), penicillin, streptomycin, and trypsin from Gibco (Grand Island, NY, USA). The cell counting kit-8 (CCK-8) was purchased from Dojindo (Kumamoto, Japan). Enzyme-linked immunosorbent assay (ELISA) kits were acquired from CUSABIO (Wuhan, China). The TRAP staining kit was obtained from Solarbio (Beijing, China).

**Human peripheral blood samples and DXA examination**

This study was carried out in full compliance with the Declaration of Helsinki, and authorized by Ethics
Committee of Tongji Medical College, Huazhong University of Science and Technology, by approval number 2018 S431. All patients provided signed informed consent. Detailed information of the patients are listed in Table 1, and descriptive statistics for the obtained sample is listed in Table 2.

**Preparation of osteoclast precursors**

Male C57BL/6 mice (5 weeks old) were purchased from the Center of Experimental Animals, Tongji Medical College, Huazhong University of Science and Technology. Osteoclast precursors (Bone marrow derived-macrophages, BMDMs) were obtained as previously described [28]. Briefly, bone marrow cells were harvested from mice femurs and tibias. After the red blood cells were lysed with RBC lysis buffer (Servicebio, Wuhan, China), the precipitated cells were cultured overnight in α-MEM medium (Gibco, Grand Island, NY, USA) with addition of 10% fetal bovine serum (Gibco) and 1% Penicillin–Streptomycin Solution (Gibco). Nonadherent cells were cultured in the presence of 30 ng/mL M-CSF for 5 d and differentiated into osteoclast precursors. Approximately 1 × 10⁴ osteoclast precursors were then added to a 96-well culture plate and differentiated into mature osteoclasts with 30 ng/mL M-CSF and 50 ng/mL RANKL.

**Cell Counting Kit 8 (CCK8)**

For the CCK-8 assay, approximately 1 × 10⁴ osteoclast precursors were added into 96-well plates and cultured overnight. The 30 ng/mL M-CSF and 50 ng/mL RANKL were added to induce osteoclast differentiation with or without various concentrations of metformin for 5 d. The medium was replaced with serum-free medium containing CCK-8 reagent and incubated for 2 h, followed by detection of absorbance at 450 nm.

**Osteoclastogenesis assay in vitro**

Approximately 1 × 10⁴ osteoclast precursors were added into each well of 96-well plate and cultured overnight. The medium was replaced with differentiation medium with or without metformin and incubated for 5 d. TRAP staining was carried out in accordance with the manufacturer’s instructions. TRAP-positive cells with greater

**Table 1 Sample information included in this study**

| Sample | Gender | Age | Main condition | Drug | Dosage of metformin (g/d) | Treatment period of metformin (Year) | Years since diagnosis of T2DM | Years since menopause |
|--------|--------|-----|----------------|------|--------------------------|-------------------------------------|-------------------------------|----------------------|
| 1      | F      | 57  | 2-DM           | None | 0                        | 0                                   | 4.2                           | 9.5                  |
| 2      | F      | 65  | 2-DM           | Glimepiride | 0                        | 0                                   | 5.3                           | 15.1                 |
| 3      | F      | 59  | 2-DM           | None | 0                        | 0                                   | 3.8                           | 5.6                  |
| 4      | F      | 57  | 2-DM           | None | 0                        | 0                                   | 4.5                           | 8.2                  |
| 5      | F      | 59  | 2-DM           | None | 0                        | 0                                   | 5.1                           | 10.5                 |
| 6      | F      | 60  | 2-DM           | Xiaoke | 0                        | 0                                   | 4.1                           | 11.7                 |
| 7      | F      | 62  | 2-DM           | None | 0                        | 0                                   | 3.6                           | 13.8                 |
| 8      | F      | 55  | 2-DM           | None | 0                        | 0                                   | 4.6                           | 6.1                  |
| 9      | F      | 58  | 2-DM           | Metformin | 2                        | 2.3                                 | 4.8                           | 8.9                  |
| 10     | F      | 64  | 2-DM           | Metformin | 2                        | 1.8                                 | 3.5                           | 15.8                 |
| 11     | F      | 65  | 2-DM           | Metformin | 2                        | 2.5                                 | 3.8                           | 14.6                 |
| 12     | F      | 55  | 2-DM           | Metformin | 2                        | 2                                   | 4.6                           | 5.9                  |
| 13     | F      | 59  | 2-DM           | Metformin | 2                        | 1.9                                 | 5.1                           | 9.8                  |
| 14     | F      | 57  | 2-DM           | Metformin | 2                        | 1.6                                 | 3.4                           | 7.4                  |
| 15     | F      | 63  | 2-DM           | Metformin | 2                        | 2.4                                 | 6.2                           | 13.5                 |
| 16     | F      | 64  | 2-DM           | Metformin | 2                        | 2.1                                 | 5.3                           | 15.4                 |

F, Female; 2-DM, Type 2 diabetes mellitus

**Table 2 Descriptive statistics for the obtained sample**

|                     | Mean age (Year) | Mean time after menopause (Year) | Mean time diagnosis of T2DM (Year) |
|---------------------|-----------------|----------------------------------|-----------------------------------|
| Control group       | 59.3±3.2        | 10.1±3.4                         | 4.4±0.6                           |
| Metformin group     | 60.6±3.8        | 11.4±3.9                         | 4.6±1.0                           |
| P                   | 0.45            | 0.47                             | 0.6491                            |
than three nuclei were considered as mature osteoclasts. Osteoclastogenic ability was detected by quantification of the TRAP-positive area compared with the total area.

Animal models and treatment
We used the ovariectomized (OVX) mice model in specific pathogen-free (SPF) facilities as previously described [29]. All animal studies were performed following protocols approved by the Laboratory Animal Center, Tongji Medical College, Huazhong University of Science and Technology and were carried out as regulated by the Tongji Medical College Animal Care and Use Committee. Eight-week-old female C57BL/6 mice were randomly distributed into three groups: sham group (served as controls), model group (mice subjected to bilateral OVX and treated with vehicle), and treatment group (mice underwent bilateral OVX and treated with metformin or E2F1-siRNA).

Briefly, mice were weighed and anesthetized with 1% pentobarbital by intraperitoneal injection, and then subjected to bilateral OVX or a sham operation. Four weeks later, mice were treated with metformin intraperitoneally (100 mg/kg) in the treatment group three times per week for 4 weeks. E2F1-RNAi (250 nmol/kg) was administrated through tail vein to the mice in the treatment group twice per week for 4 weeks. E2F1-RNAi was kept in 4% paraformaldehyde (PFA) for 20 min, permeabilized with 0.5% Triton X-100 for 10 min and then blocked with 5% goat serum for 30 min. After washing three times using PBS, the fixed cells were incubated with the primary antibodies (LC3, diluted 1:100) at 4 °C overnight, followed by DAPI staining for 10 min. Finally, proteins were separated on a 10% SDS-PAGE gel. The original bands are presented in Additional file 1.

Immunofluorescence staining
Approximately 1 × 10⁴ osteoclast precursors were seeded into each well of a 96-well plate and cultured overnight. Cells were treated with metformin for 24 h in the presence of 30 ng/mL M-CSF and 50 ng/mL RANKL. After treatment, cells were kept in 4% paraformaldehyde (PFA) for 20 min, permeabilized with 0.5% Triton X-100 for 10 min and then blocked with 5% goat serum for 30 min. After washing three times using PBS, the fixed cells were incubated with the primary antibodies (LC3, diluted 1:100) at 4 °C overnight, followed by DAPI staining for 5 min. Finally, the cells were observed using a digital microscope system (IX81; Olympus, Japan).

Pit formation assay
Approximately 1 × 10⁴ osteoclast precursors were seeded into each well of a 96-well plate and cultured overnight. Then, cells were incubated with 30 ng/ml M-CSF and 50 ng/ml RANKL and the medium was changed every 2 days. After 5 days, osteoclasts were digested with collagenase and seeded into a Corning® Osteo Assay Surface 96-well Plate, and cultured for 4 days with metformin in the presence of 30 ng/ml M-CSF and 50 ng/ml RANKL. The culture medium was replaced and the surface was washed with 0.5% sodium hypochlorite. The plate was washed twice with PBS and left to dry at room temperature for 3 h. Finally, the resorbing area was visualized using a digital microscope system and analyzed with the ImageJ software.

Enzyme-linked immunosorbent assay (ELISA)
Blood supernatants were collected and then the levels of β-CTX and TRACP-5b were measured using an ELISA kit (CUSABIO, CSB-E08490h, CSB-E08492m, CSB-E11224h, CSB-E12782m, Wuhan, China) according to the instruction manual.

Western blotting
Osteoclast precursors (4 × 10⁵ cells per well) were seeded into six-well plates and cultured overnight. After metformin treatment, total protein was extracted using a RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 1% NP-40 and 0.5% sodium deoxycholate) with a proteinase inhibitor cocktail. Next, 10 μg protein was analyzed on 10% or 12.5% SDS-PAGE and electrophoretically transferred onto polyvinylidene fluoride (PVDF) membranes. After blocking with nonfat milk for 2 h, the PVDF membranes were incubated with specific antibodies at 4 °C overnight. Next, the membranes were washed three times for 10 min with TBS-T and incubated with anti-rabbit secondary antibodies for 1 h at room temperature. After three washes with TBS-T, the membranes were incubated in chemiluminescent substrate and visualized using the GeneGnome HR Image Capture System. The original bands are presented in Additional file 1.

Co-immunoprecipitation (Co-IP)
Osteoclast precursors were treated with or without metformin in the presence of M-CSF and RANKL. The IP analysis buffer added to PMSF protease inhibitor and phosphatase inhibitor Cocktail (Proteintech; Wuhan, China) were used to lyse the cells for 30 min and precipitates were collected by centrifugation (12,000 rpm). Then 100 μg of total protein was incubated with anti-BECN1 (5 μg) or anti-BCL2 (5 μg) or anti-BNIP3 (5 μg) or non-specific IgG antibodies overnight at 4 °C on a rocker. Among them, total protein treated with non-specific IgG antibody served as a negative control. Then, the immunocomplexes were collected with 20 μl of protein A/G-sepharose beads (Proteintech) and the proteins were denatured by boiling in SDS loading buffer for 10 min. Finally, proteins were separated on a 10% SDS-PAGE gel. The original bands are presented in Additional file 1.
Micro-CT analysis
Micro-computed tomography (micro-CT) (Bruker SkyScan 1176 scanner mCT system) was used to analyze the femur structure. Under the analysis conditions with 37 kV and 121 mA, 300 section planes were examined from the growth plate. To perform the morphometric analysis, we obtained the following trabecular parameters, BMD, BV/TV (%), BS/TV, and Tb.N, from the software of CTan and CTvol.

Hematoxylin and Eosin (H&E) Staining and TRAP Staining
The femurs were collected from mice and fixed in 4% paraformaldehyde for 4 d. The samples were subsequently decalcified for 2 weeks using 10% tetracycline-EDTA (Servicebio) and 4-μm-thick paraffin-embedded sections were prepared with H&E and TRAP staining for further analysis. H&E and TRAP staining were carried out according to the manufacturers’ instructions (Solarbio). The images were obtained by microscopy and histological analyses were performed using ImageJ software.

Overexpression lentivirus transfection
Osteoclast precursors were seeded into six well plates at 4 × 10^5 cells/well. The cells were transfected with lentiviral particles for overexpression of BNIP3 or E2F1 (Genechem, Shanghai, China) using polybrene in the presence of 30 ng/mL M-CSF. After 48 h and washing three times to stop the infection, cells were incubated with vehicle or metformin in the presence of 30 ng/mL M-CSF and 50 ng/mL RANKL.

In vivo E2F1-siRNA
E2F1-siRNA was purchased from RIBOBIO (Guangzhou, China). The E2F1-siRNA targeting sequence was 5’-GACGTGTCAGGACCTTCGTT-3’. To enhance stability in serums and transfection efficiency, cholesterol and methylation-modified siRNA were performed.

For siRNA-mediated gene knockdown in vivo, E2F1-siRNA was administrated by tail vein to the ovariectomized mice twice per week for 4 weeks, and then the knockdown efficiency was evaluated.

Autophagy monitoring
Osteoclast precursors were infected with tandem GFP-red fluorescent protein (RFP)-LC3 lentivirus (Genechem) for 16–18 h according to the manufacturer’s instructions. After 3 d, cells were treated with metformin or/and rapamycin (RAPA, 10 nM) for 24 h to observe the autophagy flux. When autophagy was induced, the overlap between GFP and RFP was shown as yellow dots representing autophagosomes. When autophagosomes fuse with lysosomes and form autolysosomes, the GFP degrades in the acidic environment, but RFP-LC3 remains evident as red dots.

Statistical analysis
All experiments were conducted at least three times and are presented as the mean ± standard deviation. One-way analysis of variance for three groups and Student’s t-test for two groups were performed using GraphPad Prism 8.0 (GraphPad Software). A value of p < 0.05 was considered statistically significant.

Results
Change in bone resorption and BMD with metformin in postmenopausal women with T2DM
In order to investigate whether metformin contributes to bone health, we carried out a study using blood samples from 16 postmenopausal women taking or not taking metformin for T2DM, and then we determined the levels of β-CTX and TRACP-5b in the serum, reflecting osteoclast activity and bone resorption. The results showed that the levels of β-CTX and TRACP-5b in the serum were markedly decreased in patients with metformin treatment (Fig. 1A). In addition, these patients agreed to undergo testing of dual-energy x-ray absorptiometry (DXA), and we found that treatment with metformin led to comparable results in bone mineral density (BMD) at lumbar spine 1 (LS1) (Fig. 1B), total hip (TH) (Fig. 1C), and femoral neck (FN) (Fig. 1D). Accordingly, the mean BMD T-score at LS1, TH and FN showed significant increases in response to metformin treatment (Fig. 1B–D).

Metformin attenuates OVX-induced bone loss in vivo
To prove the protective effect of metformin against OVX-induced bone loss in vivo, blood samples were collected from ovariectomized mice that had or had not received metformin. Metformin treatment for 4 weeks in ovariectomized mice resulted in lower concentration of the circulating bone resorption markers, including β-CTX and TRACP-5b, compared with vehicle-treated ovariectomized mice (Fig. 2A). To further explore the bone microstructural changes after metformin treatment, microcomputed tomography (micro-CT) was used to evaluate various indicators in the distal femur, including BMD, bone volume/total volume (BV/TV), trabecular bone surface area/total value (BS/TV), and trabecular number (Tb. N). The results highlighted reduced bone mass (BMD and BV/TV) and deteriorated trabecular architecture (Tb. N) in the ovariectomized mice, and treatment with metformin attenuated this loss of bone and bone quality (Fig. 2B, C).
and eosin staining showed that the ovariectomized mice had trabecular bone loss compared with the sham-operated mice, whereas bone loss was reduced in ovariectomized mice administered with metformin (Fig. 2D, E). It is well known that osteoporosis after menopause is often attributed to increased osteoclastic bone resorption caused by estrogen deficiency [30]. We therefore investigated the effects of metformin on osteoclast formation and carried out TRAP staining to investigate the distribution of osteoclasts in the femur. As shown in Fig. 2F, G, the number of osteoclasts was significantly increased in ovariectomized mice, while metformin administration significantly reduced the number of osteoclasts.

Studies have indicated that metformin suppressed osteoclast formation potentially through stimulating OPG and reducing RANKL expression in vivo [17]. To further test whether other mechanisms may be involved, we examined the differentiation potential of osteoclast precursors isolated from sham mice, ovariectomized mice, and ovariectomized mice treated with metformin with the addition of equal amounts of RANKL in vitro (Fig. 3A). Osteoclast precursors were stimulated with 30 ng/mL M-CSF and 50 ng/mL RANKL for 5 d, and their differentiation into mature osteoclasts was assessed by TRAP staining. In a manner consistent with our observation of a decrease in bone loss, we found fewer TRAP-positive osteoclasts along with smaller osteoclasts in ovariectomized mice administered with metformin, as compared to those in ovariectomized mice (Fig. 3B, C). Taken together, these data suggest that metformin has protective effect against OVX-induced bone loss in vivo at least partially through inhibition of osteoclast formation and activity via other mechanisms in addition to OPG/RANKL.

**Metformin suppresses RANKL-induced osteoclast differentiation in vitro**

We next investigated metformin in osteoclast differentiation in vitro. To directly test this, osteoclast precursors isolated from 5-week-old male C57BL/6 mice were stimulated with or without metformin in the absence/presence of RANKL, and then osteoclastogenesis was assessed by TRAP staining (Fig. 4A). Before in vitro studies, the cell counting kit 8 (CCK8) analysis was performed to determine the appropriate concentration of metformin (Fig. 4B). As shown in Fig. 3C, metformin below 20 μM had nearly no cytotoxic effects on the osteoclast precursors. Furthermore, RANKL treatment
resulted in notably greater osteoclast number and size, whereas an addition of metformin in the osteoclast precursors significantly reduced the number of TRAP-positive cells in a dose-dependent manner (Fig. 4D, E). To confirm the effects of metformin on RANKL-induced osteoclast precursors differentiation into mature osteoclasts, metformin was added to osteoclasts differentiation cultures beginning on d 0 and d 3 for osteoclast precursors. The results indicated that metformin inhibited osteoclastogenesis on the first day but had little effect on osteoclastogenesis at later stages (Fig. 4F, G). However, a high concentration of metformin may have an effect on osteoclast differentiation at later stages via promoting osteoclast precursors or osteoclasts apoptosis [31], which needs further verification. Furthermore, to verify the direct effect of metformin on the bone
resorption activity of mature osteoclasts, pit formation assay was performed. The results indicated that treatment with metformin could significantly decreased the bone resorption area compared with vehicle treatment (Fig. 4H, I). In summary, metformin could directly inhibit RANKL-induced osteoclast differentiation and activity in vitro.
Metformin inhibits osteoclast differentiation via decreasing autophagy of osteoclast precursors

There are increasing findings demonstrating that, in addition to the interrelation between autophagy and bone physiology, autophagy plays a crucial role in the onset and progression of pathological osteoporosis [32, 33]. Moreover, downregulation of autophagy inhibits ovariectomy-induced bone loss [14]. In the present study, we found obvious accumulation of LC3 puncta in osteoclast precursors isolated from ovariectomized mice as compared with the corresponding control. However, metformin-treated ovariectomized mice manifested significantly fewer LC3 puncta compared with the vehicle-treated group (Fig. 5A, B).

To further confirm these data, we used tandem GFP-red fluorescent protein (RFP)-LC3 lentivirus to infect osteoclast precursors for labeling and tracking LC3. Red puncta indicate autophagosomes, and yellow puncta overlapping red and green fluorescence are autophagosomes. The count of red and yellow puncta could be used to infer the intensity of autophagy flow [34]. The results shown in Fig. 5C demonstrate that metformin could dramatically lessen the intensity of autophagy flux during RANKL-induced osteoclast differentiation, in which the white arrows represent autophagolysosomes and the blue arrows represent autophagosomes, then quantification of the number of autophagolysosomes (red) and autophagosomes (yellow) in Fig. 5C was shown in Fig. 5D, which remained consistent. Electron microscopy imaging results were in line with this, suggesting metformin could inhibit the formation of autophagosomes and/or autophagolysosomes during osteoclastogenesis (Fig. 5E, F). In order to expound the role of metformin-downregulated autophagy during osteoclast differentiation, rapamycin, a common autophagic activator, was used to activate metformin-downregulated autophagy. After introduction of rapamycin, metformin-reduced autophagy was reactivated, in which metformin...

Fig. 5 Metformin inhibits osteoclast differentiation via decreasing autophagy. A Immunofluorescence staining for LC3 in osteoclast precursors isolated from the femur and tibia of sham group mice, OVX group mice, and OVX+MET group mice. B Quantification of the LC3 puncta per cell in (A). C, D After infection with tandem GFP-red fluorescent protein (RFP)-LC3 lentivirus, osteoclast precursors were treated with metformin and/or rapamycin (10 nM) for 24 h in presence of 30 ng/mL M-CSF and 50 ng/mL RANKL, and then the fluorescence was observed by fluorescence microscopy and quantitative analysis was performed. E, F metformin and/or rapamycin were used to treat osteoclast precursors for 24 h, and then the formation of autophagosomes and/or autolysosomes in osteoclast precursors were observed under transmission electron microscopy. G After metformin or/and rapamycin, TRAP-stained multinucleated osteoclasts. H Quantitative analysis of the area of TRAP-positive osteoclasts. Data are presented as means±5D of 3 independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001, ns, non-significant)
could no longer fulfill its role in inhibiting autophagosomes or/and autophagolysosomes during osteoclastogenesis (Fig. 5C–F). Furthermore, rapamycin cotreatment blocked the ability to suppress osteoclast formation (Fig. 5G, H). Overall, metformin suppressed osteoclast differentiation most likely via downregulation of autophagy in osteoclast precursors, while rapamycin cotreatment could counteract these beneficial effects.

Metformin regulates autophagy through a mechanism involving BECN1 and BNIP3

After substantiating the cellular effects of metformin, we aimed to further explore the intrinsic molecular mechanism of metformin-downregulated autophagy. There have been numerous studies indicating that metformin regulates autophagy in an AMPK-dependent manner [35, 36]. However, the AMPK mechanism which was activated by metformin to enhance autophagy seems inconsistent with its effects on osteoclast differentiation. Thus, inhibitory effects on osteoclast differentiation caused by metformin may involve other mechanisms rather than those of the AMPK pathway. BECN1, as a highly evolutionarily conserved molecule of autophagy, is currently widely recognized for its role in autophagosome formation and bone homeostasis [37, 38] and can be regulated at several levels, including transcription, translation and post-translational modifications [39, 40]. Therefore, we subsequently analyzed whether the change of BECN1 expression participated in metformin-downregulated autophagy. As shown in Fig. 6A, B, treatment with metformin could downregulate the expression level of BECN1 protein in a dose-dependent manner.

Although the BCL2 family was initially considered to be important regulators of apoptosis [41], it is now increasingly recognized that it plays a crucial role in regulating not only apoptosis but also autophagy [42]. Thus, we next determined whether BCL2-family proteins participate in the mechanism of metformin-downregulated autophagy. As shown in Fig. 6A, B, we found a marked diminution in the expression level of the BH3-only protein, BNIP3, after metformin treatment compared with RANKL treatment only in a dose-dependent manner. Overexpression of BNIP3 by lentiviral transfection increased the LC3II protein expression, but did not affect the expression levels of BECN1 protein (Fig. 6A, B). These results indicated that metformin decreased autophagy of osteoclast precursors probably through a mechanism involving BECN1 and BNIP3. However, the downregulated level of BECN1 protein is independent from the level of BNIP3. Therefore, it is important to disentangle the relationship between BECN1 and BNIP3.

Recently, some studies revealed that BECN1 could interact with BCL2 to suppress autophagy [43, 44]. Given that BNIP3 is established as a BH3-only protein, it is most likely that metformin-mediated BNIP3 downregulation might result in an alteration in the connection between BECN1 and BCL2. In fact, co-immunoprecipitation revealed that metformin treatment lessened the binding between BNIP3 and BCL2 (Fig. 6C), followed by promoting the association between BECN1 and BCL2 and reduction of the free BECN1 level as compared with RANKL treatment alone (Fig. 6D, E). However, overexpression of BNIP3 abolished the metformin-mediated BNIP3 diminishment, and promoted the BNIP3 and BCL2 interaction, leading to disassociation between BCL2 and BECN1 (Fig. 6C–E).

Metformin-mediated autophagy downregulation via BECN1 and BNIP3 is E2F1 dependent

Although E2F1 is widely accepted as playing a crucial role in cell cycle and metabolism [37], a recent study revealed that the E2F1 level in postmenopausal women with high BMD is significantly decreased as compared with that in postmenopausal women with low BMD based on exon array analysis in peripheral blood monocytes (PBM) [45]. Therefore, it is very likely that E2F1 plays an important role in osteoclast formation and activity. We next examined the role of E2F1 in the regulation of autophagy by BECN1 and BNIP3. As shown in Fig. 7A, B, metformin treatment obviously decreased the expression level of E2F1 compared with RANKL treatment only, followed by reduced expression levels of BECN1, BNIP3, and LC3II. To further ascertain the role of E2F1 in metformin-downregulated autophagy during osteoclast differentiation, we tested whether overexpression of E2F1 could abolish the reduction in metformin-mediated autophagy. Interestingly, compared with control group, lentivirus-mediated E2F1 overexpression in osteoclast precursors in the presence of M-CSF and RANKL not only sharply upregulated BECN1, BNIP3 and LC3II expression levels, but also markedly enhanced the accumulation of LC3 puncta and BECN1 fluorescence intensity, and finally reduced BECN1, BNIP3 and LC3-II expression levels mediated by metformin were abolished (Fig. 7A–E). Moreover, overexpression of E2F1 also resulted in significantly elevated osteoclast formulation as compared with the control group, while the effect could not be alleviated by metformin (Fig. 7F, G), which was consistent with LC3 puncta and BECN1 fluorescence intensity in osteoclast precursors. On the whole, these results suggested that the downregulation of autophagy after metformin treatment in osteoclast precursors is mediated by the reduction of E2F1 levels, and E2F1 is required for
Fig. 6  Metformin regulates autophagy through a mechanism involving BECN1 and BNIP3. A Cell lysates of osteoclast precursors were used to examine the expression of BECN1, BNIP3 and LC3 proteins by western blot. After overexpression of BNIP3 (Lv-BNIP3), osteoclast precursors were treated with metformin (0, 10, 20 μM) for 5 d in the presence of 30 ng/mL M-CSF and 50 ng/mL RANKL. B The quantitative analysis of immunoblots relative to GAPDH protein level in (A). The results were from pairwise comparisons within- and between-group. C Osteoclast precursors were treated as in (A), and the cell lysates were performed to co-immunoprecipitation with BCL2 antibody, followed by immunoblotting with the indicated antibodies. Among them, IgG group was considered as negative control. D, E Osteoclast precursors were treated as in (A), and the cell lysates were subjected to co-immunoprecipitation with either BCL2 or BECN1 antibody, followed by immunoblotting with the indicated antibodies. Among them, IgG group was considered as negative control. Values displayed are means ± SD of 3 independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001, ns, non-significant)
the inhibition of the autophagy upon downregulation of BECN1 and BNIP3 levels.

E2F1-siRNA administration rescues OVX-related bone loss in vivo

In order to test the effects of E2F1 in vivo inhibition on OVX-induced bone loss, ovariectomized mice were treated with E2F1-siRNA for 4 weeks. To examine the effect of E2F1 administration, we performed immunohistochemical analysis for E2F1 and BNIP3 levels, and the results revealed that treatment with E2F1-siRNA dramatically knocked down the expression of E2F1, followed by decreasing BNIP3 level in femurs as compared with vehicle-treated ovariectomized mice (Fig. 8A, B), which demonstrated that E2F1-siRNA administration via tail-vein was effective method. Relative to the vehicle-treated group, E2F1 siRNA-treated ovariectomized mice had better trabecular bone microarchitecture in the femur (Fig. 8C). Morphometric analyses of trabecular parameters confirmed the decreased bone mass in BMD, BS/TV, BV/
TV, and Tb.N in ovariectomized mice, while the OVX-induced deterioration of the trabecular microarchitecture could be reversed by E2F1 siRNA administration (Fig. 8D). Furthermore, the bone tissue microarchitecture was evaluated by histological staining of tissue sections with H&E. The results showed that the low-bone mass phenotype in ovariectomized mice was obvious in H&E-stained tissue samples (Fig. 8E) and this was verified by quantitative histomorphometric analysis of Tb.N (Fig. 7F). There is growing awareness that excessive osteoclast formation and bone resorption are often the latent causes of bone loss after the menopause.
Therefore, we performed TRAP staining of femur bone sections to assess osteoclast numbers and activity. As shown in Fig. 8G and H, femur sections from ovariectomized mice administered E2F1 siRNA had presented decreased numbers of osteoclasts than other ovariectomized mice. Together, these results showed that silencing of E2F1 in ovariectomized mice results in amelioration of OVX-induced bone loss.

Discussion
In this study, we showed for the first time that metformin exerts a bone protective action against postmenopausal bone loss through inhibition of OVX-induced autophagosome synthesis during osteoclastogenesis. This process is mediated by the E2F1-BNIP3 and BECN1 signaling pathways, instead of a conventional metformin-AMPK pathway. Mechanistically, metformin treatment inhibited estrogen deficiency-induced E2F1 upregulation, followed by downregulated expression levels of BECN1 and BNIP3 protein, which subsequently suppressed the binding between BNIP3 and BCL2, thus promoting the association of BECN1 and BCL2. In this way, OVX-activated autophagy upregulation is suppressed by metformin, leading to the alleviation of OVX-induced bone loss (Fig. 9A).

It is well established that metformin has a protective effect on bone health [25]. With our initial findings, we also confirmed that metformin use reduced bone resorption and improved bone quality in postmenopausal
women and ovariectomized mice. Furthermore, we also observed that the beneficial effect on bone is achieved at least in part via decreased osteoclast formation and activity. In addition, the protective effect of metformin may be also attributed to activation of osteogenic differentiation via RUNX2 and AMP-activated protein kinase (AMPK)/upstream transcription factor 1 (USF1)/small heterodimer partner (SHIP) signaling [23–25], activation of AMPK signaling pathway and subsequent enhancement in eNOS and BMP-2 production in MC3T3-E1 cells [46], inhibition of GSK3β in human mesenchymal stem cells (hBMSCs) [47] and decrease in reactive oxygen species level and adipogenic differentiation in adipose-driven multipotent mesenchymal stem cells in vitro [48]. Moreover, metformin treatment activates peroxisome proliferator–activated receptor γ coactivator 1-α (PGC-1α) in osteoblasts, promoting osteoblast survival and function in high-glucose condition and reversing osteopenia in diabetic mice [49].

We found that other mechanisms than OPG/RANKL may be involved in this process when we investigated the change in differentiation capacity in osteoclast precursors after metformin treatment in the presence of 30 ng/ml M-CSF and 50 ng/ml RANKL in vitro. Then, given that induction of autophagy is crucial for osteoclast differentiation of monocytes [50], autophagic flux in osteoclast precursors from femurs and tibias of ovariectomized mice with or without metformin treatment or osteoclast precursors after metformin treatment were detected, and we found that the increased autophagy level is associated with increased osteoclast formation and bone resorption in postmenopausal bone loss and metformin treatment sharply downregulated the autophagic level. These findings were consistent with previous reports that specific deletion of Atg7 in monocytes and systemic delivery of chloroquine, an autophagy inhibitor, could decrease osteoclast activity and finally alleviate bone loss in ovariectomized mice [14]. However, the role of autophagy in osteoclast and osteoblast activity after metformin stimulation is uncertain. Autophagy upregulation is related to the osteogenic differentiation of MSCs [45], and estrogen deficiency downregulates autophagic activity in osteoblasts, promoting the development of osteoporosis [51]. These studies showed that activation of autophagy in osteoblast precursors is beneficial in mitigating estrogen deficiency-induced osteoporosis. However, whether metformin promotes/inhibits autophagy in osteoblasts was not explored further in this study. Nevertheless, it is reasonable to believe that the downregulated autophagy level in osteoclast precursors mediated by metformin plays a dominant role in reversing the postmenopausal bone loss in this study. In addition, previous studies also showed that metformin treatment could inhibit osteoclast formation and activity through PI3K/Akt and ERK signaling [31], decreasing the inflammatory response and oxidative stress [52], reducing the RANK expression in osteoclast precursors [53], promoting the polarization of macrophages to an anti-inflammatory phenotype [54], reducing RANKL expression and stimulating OPG expression in osteoblasts [17, 26], and prevent bone loss. Furthermore, previous studies indicated that PI3K/Akt and ERK signaling [55–57], inflammation factors signaling [58], OPG/RANKL signaling and RANK signaling [56, 59] might be also involved in regulating autophagic level during osteoclast differentiation and bone resorption (Fig. 9B). Therefore, autophagy might play a crucial role in the inhibition of bone loss by metformin.

We next investigated the involvement of metformin in autophagy more specifically to identify the regulatory target in osteoclast precursors. E2F1 was first identified as a protein that belongs to the E2F family, which is known for binding to the retinoblastoma protein (pRB), a tumor inhibitor mutated in many types of cancer [60, 61]. Recently, it was also reported that E2F1 was involved in regulation of osteoclastogenesis and autophagy [62–65]. For example, E2F1 promoted osteoclastogenesis by regulating glycolytic metabolism [62]. In searching for factors associated with low BMD in postmenopausal women, Zhou et al. reported that downregulated E2F1 was related to higher BMD in the hip [45]. In addition, it is known that E2F1 is involved in regulating the autophagy process in some tumors [62, 63, 65], but whether it participates in regulation of autophagy activity in osteoclast precursors remains unclear. Indeed, it was found that the level of E2F1 was decreased in response to metformin stimulation, while overexpression of E2F1 abolished the suppressive effect of metformin on RANKL-induced autophagy level in osteoclast precursors, followed by restoring metformin-associated inhibition of osteoclast differentiation. Furthermore, E2F1 silencing effectively suppressed osteoclastogenesis in vivo.

BECN1, a novel Bcl-2-homology (BH)-3 domain-only protein, is considered as one of the most important regulators of autophagy in the autophagy process [66, 67]. However, BECN1-induced autophagy would be inhibited when BECN1 is bound to BCL2 [68]. In this study, we have focused on BECN1 to specifically determine the regulation mechanism of metformin in the autophagy process. Indeed, we observed that metformin-mediated E2F1 downregulation not only suppressed BECN1 expression but also reduced the expression of the BNIP3 protein that competitively binds to BECN1 with BCL2 through binding with BECN1 and BNIP3 promoters [66, 69]. Furthermore,
dissociation of BNCN1 from BECN1/BCL2 complex was reduced, and autophagy was downregulated, leading to inhibition of osteoclastogenesis.

However, there are some limitations in our present study. Among these, one of the most important is that there might be some side effects associated with metformin or E2F1 siRNA therapy when the systemic use of metformin or E2F1 siRNA. Based on this, the problem could be addressed through at least three methods as follows: (1) Metformin or E2F1 siRNA was loaded in biomaterials targeted bone or osteoclasts [70, 71], such as CXCR4 + exosomes [72] and alendronate functionalized nanoparticles [73]. (2) Local administration of metformin or E2F1 siRNA in some osteoporotic disorders, such as intertrochanteric fractures and vertebral fractures. (3) Bone-target modification for metformin or E2F1 siRNA [74, 75]. Together, the above methods may be better therapeutic choices than modes of traditional administration, which seem to reduce the off-target effects.

Conclusion
Collectively, our study confirmed that the beneficial effects of metformin on postmenopausal bone loss could be attributed, at least in part, to its role in downregulating the OVX-activated autophagy level during osteoclast formation. Mechanistically, we also demonstrated that the inhibition of OVX-activated autophagy level upon metformin treatment was associated with E2F1-BECN1 and E2F1-BNIP3 signaling pathway. These insights about metformin will provide clues for future treatment of postmenopausal osteoporosis through modulating E2F1.

Abbreviations
B-CTX: B-terminal telopeptide of type I collagen; B isoform; TRAP-5b: Tartrate-resistant acid phosphatase type 5b; TRAP: Tartrate-resistant acid phosphatase; BMD: Bone mineral density; BV/TV: Bone volume per tissue volume; Tbn: Trabecular number; LC3: Microtubule-associated protein 1 light chain 3; Bec-lin1: Autophagy related; CTSK: Cathepsin K; NFAc1: Nuclear factor of activated T cells 1; ACP5: Acid phosphatase 5; Micro-CT: Microcomputed tomography; qRT-PCR: Quantitative reverse-transcriptase polymerase chain reaction; Co-IP: Co-immunoprecipitation; GFP: Enhanced green fluorescent protein; M-CSF: Macrophage colony-stimulating factor; RANKL: Receptor activator of nuclear factor-κB (RANK); PM: Postmenopausal women; MET: Metformin; T2DM: Type 2 diabetes mellitus.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12964-022-00966-5.

Additional file 1. Supplementary material.

Author contributions
XX, LH and BM performed most of the experiments, wrote the paper, and analyzed the data. HX, YH, LC provided the data processing assistance and the experimental assistance. ACP and YE provided writing assistance. CY and ZL proofread the manuscript. WZ, HL and GL designed and directed the study. All authors read and approved the final manuscript.

Funding
This work was supported by the National Science Foundation of China (No. 82002313, No. 82072444), the National Key Research & Development Program of China (No. 2018YFC2010502, 2018YFB1105705); Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration (No. 2020kghm008).
13. Shi J, Wang L, Zhang H, Jie Q, Li X, Shi Q, et al. Glucocorticoids: Dose-related effects on osteoclast formation and function via reactive oxygen species and autophagy. Bone. 2015;79:22–32.

14. Lin HY, Chen CW, Kagwira R, Liang R, Beyar C, Distler A, et al. Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss. Ann Rheum Dis. 2016;75:1203–10.

15. Hidayat K, Du X, Wu MJ, Shm BM. The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta-analysis of observational studies. Obes Rev. 2019;20:1494–503.

16. Blumel JE, Arteaga E, Aedo S, Arniola-Montenegro J, López M, Martino M, et al. Metformin use is associated with a lower risk of osteoporosis: in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study. Gynecol Endocrinol. 2020;36:421–2.

17. Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, et al. Metformin stimulates osteoprotectorin and reduces RANKL expression in osteoblasts and ovariectomized rats. Cell J Biochem. 2011;11:2902–9.

18. Sun HJ, Lee J, Lee SY, Kim EK, Park MJ, Kim KW, et al. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis. Mediators Inflamm. 2014;2014:973866.

19. Matsuoka Y, Morimoto S, Fujishiro M, Hayakawa K, Katoaka Y, Suzuki S, et al. Metformin repositioning in rheumatoid arthritis. Clin Exp Rheumatol. 2021;39:763–8.

20. Xie Z, Lai K, Ebihara K, Lozano P, He C, Pennington B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011;60:1770–8.

21. Li J, Gui Y, Ren J, Liu X, Feng Y, Zeng Z, et al. Metformin protects against cisplatin-induced tubular cell apoptosis and acute kidney injury via AMPKα-regulated autophagy induction. Sci Rep. 2016;6:23975.

22. Son SM, Shin HJ, Byun J, Kook SY, Moon M, Chang YJ, et al. Metformin facilitates amyloid-β generation by β- and γ-secretases via autophagy activation. J Alzheimers Dis. 2016;51:1197–208.

23. Shah M, Kola B, Matalevic A, Arnett TR, Viollet B, Saxon L, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone. 2010;47:309–19.

24. Sofer E, Shargorodsky M. Effect of metformin treatment on circulating osteoprotectorin in patients with nonalcoholic fatty liver disease. Hepatol Int. 2016;10:169–74.

25. Bahrambeigi S, Yousefi B, Rahimi M, Shafiei-Irannejad V. Metformin; an old drug with a new role in osteoporosis and its mechanism. Pharmazie. 2021;76:244–8.

26. Lei X, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA. 2003;100:2432–7.

27. Ma X, Godar RJ, Liu H, Diwan A. Enhancing lysosome biogenesis attenuates BMP3-induced cardiomyocyte death. Autophagy. 2012;8:297–309.

28. Zhou Y, Zhu W, Zhang L, Zeng Y, Xu C, Tian Q, et al. Transcriptional data identified key transcription factors for osteoporosis in Caucasian women. Calcif Tissue Int. 2018;103:581–8.

29. Kanazawa Y, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun. 2008;357:414–9.

30. Ma J, Zhang ZL, Hu XT, Wang XT, Chen AM. Metformin promotes differentiation of human bone marrow derived mesenchymal stem cells into osteoblast via GSK3β inhibition. Eur Rev Med Pharmacol Sci. 2018;22:7962–8.

31. Marycz K, Tomaszewski KA, Kornicka K, Henry BM, Wroński S, Tarasiuk J, et al. Metformin decreases reactive oxygen species, enhances osteogenic properties of adipose-derived multipotent mesenchymal stem cells in vitro, and increases bone density in vivo. Oxd Med Cell Longev. 2016;2016:758980.

32. Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, et al. Pathophysiological mechanism of bone loss in type 2 diabetes involves inverse regulation of osteoblast function by PGC-1α and skeletal muscle atrogenes: AdipoR1 as a potential target for reversing diabetes-induced osteopenia. Diabetes. 2015;64:2609–23.

33. Zhang Y, Morgan MJ, Chen K, Choksi S, Liu ZG. Induction of autophagy is essential for monocytic-macrophage differentiation. Blood. 2012;119:2895–905.

34. Pernicova I, Kelly S, Apodaca S, Sahdev A, Bestwick JP, Gabrovská P, et al. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes Endocrinol. 2020;8:278–91.

35. Araújo AA, Pereira A, Medeiros C, Brito GAC, Leitão RFC, Araújo LS, et al. Effects of metformin on inflammation, oxidative stress, and bone loss in a rat model of periodontitis. PLoS ONE. 2017;12:e0183506.

36. Tao LY, Łagosz-Ćwik KB, Hogervorst JMA, Schoenmaker T, Grabiec AM, Foerster B, et al. Diabetes medication metformin inhibits osteoclast formation and activity in in vitro models for periodontitis. Front Cell Dev Biol. 2021;9:77450.

37. Yan Z, Tian X, Zhu J, Lu Z, Yu L, Zhang D, et al. Metformin suppresses UHWMPE particle-induced osteolysis in the mouse calvaria by promoting polarization of macrophages to an anti-inflammatory phenotype. Mol Med. 2018;24:20.
55. Fu L, Wu W, Sun X, Zhang P. Glucocorticoids enhanced osteoclast autophagy through the PI3K/Akt/mTOR signaling pathway. Calcif Tissue Int. 2020;107:60–71.
56. Zhao H, Sun Z, Ma Y, Song R, Yuan Y, Bian J, et al. Antiosteoclastic bone resorption activity of osteoprotegerin via enhanced AKT/mTOR/ULK1-mediated autophagic pathway. J Cell Physiol. 2020;235:3002–12.
57. Xu X, Wang R, Wu R, Yan W, Shi T, Jiang Q, et al. Trehalose reduces bone loss in experimental biliary cirrhosis rats via ERK phosphorylation regulation by enhancing autophagosome formation. FASEB J. 2020;34:8402–15.
58. Liu W, Zhou J, Niu F, Pu F, Wang Z, Huang M, et al. Mycobacterium tuberculosis infection increases the number of osteoclasts and inhibits osteoclast apoptosis by regulating TNF-α-mediated osteoclast autophagy. Exp Ther Med. 2020;20:1889–98.
59. Xu X, Xie H, Zhao C, Li J, Morita Y, Yao Z, et al. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J Clin Invest. 2014;124:297–310.
60. Bagchi S, Weinmann R, Raychaudhuri P. The retinoblastoma protein co-ordinates with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell. 1991;65:1063–72.
61. Dyson NJ. RB1: a prototype tumor suppressor and an enigma. Genes Dev. 2016;30:1492–502.
62. Murata K, Fang C, Terao C, Giannopoulou EG, Lee YJ, Lee MJ, et al. Hypoxia-sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis. Immunity. 2017;47:66–79.e65.
63. Ruan C, Wang C, Gong X, Zhang Y, Deng W, Zhou J, et al. An integrative multi-omics approach uncovers the regulatory role of CDK7 and CDK4 in autophagy activation induced by silica nanoparticles. Autophagy. 2021;17:1426–47.
64. Polager S, Ofir M, Ginsberg D. E2F1 regulates autophagy and the transcription of autophagy genes. Oncogene. 2008;27:4860–4.
65. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonzo M, White E, et al. The RB-E2F1 pathway regulates autophagy. Cancer Res. 2010;70:7882–93.
66. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18:571–80.
67. Oberstein A, Jeffrey PD, Shi Y. Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein. J Biol Chem. 2007;282:13123–32.
68. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122:927–39.
69. Niu C, Chen Z, Kim KT, Sun J, Xue M, Chen G, et al. Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway. Autophagy. 2019;15:843–70.
70. Zhou X, Cornel EJ, Fan Z, He S, Du J. Bone-targeting polymer vesicles for effective therapy of osteoporosis. Nano Lett. 2021;21:7998–8007.
71. Dou C, Li J, He J, Luo F, Yu T, Dai Q, et al. Bone-targeted pH-responsive cerium nanoparticles for anabolic therapy in osteoporosis. Bioact Mater. 2021;6:4697–706.
72. Hu Y, Li X, Zhang Q, Gu Z, Luo Y, Guo J, et al. Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss. Bioact Mater. 2021;6:2905–13.
73. Chen Q, Zheng C, Li Y, Bian S, Pan H, Zhao X, et al. Bone targeted delivery of SDF-1 via alendronate functionalized nanoparticles in guiding stem cell migration. ACS Appl Mater Interfaces. 2018;10:25700–10.
74. Rotman SG, Griepma DW, Richards RG, Moriarty TF, Eglin D, Guillaume O. Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics. J Control Release. 2018;269:88–99.
75. Neale JR, Richter NB, Merten KE, Taylor KG, Singh S, Waite LC, et al. Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg Med Chem Lett. 2009;19:680–3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions